Cancer Research Technology
Log in Register
Menu

Info

Catalogue Number 153570
Antigen/Gene or Protein Targets Squamous Cell Carcinoma line
Synonyms SCC, Keratinocyte
Host Human
Disease Keywords Cancer, Skin Cancer, Squamous Cell Carcinoma
Model Tumour line
Relevance Keratinocyte cell line, representing the ultimate metastatic stage in a SCC cancerous transformation.

Background and Research Application
MET4 is derived from a from metastatic SCC within left axillary lymph nodes that were biopsied following the third excision. The cell lines originated as a primary tumour on the left hand. Histology of the original tumour showed an acantholytic squamous cell carcinoma. MET4 has been used to understand aggressive metastatic SCCs and is an important cell line for this specific stage in SCC cancer progression.
MET4 is the fourth cell line in a unique series of epidermal cell lines representing different stages of malignant transformation. These cell lines were derived from a single, adult, immunosuppressed individual.
Four keratinocyte lines (PM1-4) established from forehead skin are here compared with 4 squamous cell carcinoma (SCC) lines (MET1, MET2) derived respectively from a primary cutaneous tumour, two local recurrences and a distant metastasis of invasive SCC. Despite altered growth properties, the PM lines retained many features of normal keratinocytes including keratin phenotype, differentiation capacity and non-tumorigenicity in athymic mice. In contrast, from early passage, the MET lines displayed markedly reduced growth requirements, abnormal differentiation, aberrant K18 expression and tumorigenicity in athymic mice. The abnormal keratin profile of individual MET lines closely reflected the keratin phenotype of the tumour of origin. Although unusual HPV types were identified in the original tissue, there was no evidence of persistent virus within any cell line and it appears that HPV is not critical for maintenance of the immortal phenotype. The PM lines were distinctly different from invasive SCC lines and are likely to be useful in studies focusing on mutations that are important in early neoplastic progression. The SCC series represent primary, recurrent and metastatic carcinoma. Availability of such a series from the same individual will facilitate genetic analysis of the malignant process.
Production Details MET4 was derived from a metastatic SCC within the left auxillary lymph nodes that were biopsied
Research Area Cancer
Recommended Growing Conditions DMEM/5% serum, high glucose
Notes Points of Interest
MET cell lines were derived from a single immunosuppressed patient, from a primary invasive SCC on the back of the hand that subsequently recurred locally twice.

Difference Between Clones
All derived from the same individual, but from varying stages in progression of an SCC: invasive, recurrent and, subsequently metastatic. Keratinocyte lines MET1, MET2, MET3 and MET4 were derived, respectively, from an SCC excised from the back of the left hand (MET1), from 2 recurrent SCC arising at the same site in rapid succession (MET2 and 3)and from metastatic SCC within left axillary lymph nodes biopsied following the third excision (MET4).

Concentration
Vial has between 1-5 million cells as standard, however this may vary.

References

There are 6 reference entries for this reagent.

View All References

References: 6 entries

Inman et al. 2018. Nat Commun. 9(1):3667. PMID: 30202019.

The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.

Europe PMC ID: 30202019

Abikhair Burgo et al. 2018. JCI Insight. 3(17):. PMID: 30185657.

Abikhair Burgo et al. 2018. JCI Insight. 3(17):. PMID: 30185657.

Mekhdjian et al. 2017. Mol Biol Cell. 28(11):1467-1488. PMID: 28381423.

Proby et al. 2000. Exp Dermatol. 9(2):104-17. PMID: 10772384.


Add a reference

References: 6 entries

Inman et al. 2018. Nat Commun. 9(1):3667. PMID: 30202019.

The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.

Abikhair Burgo et al. 2018. JCI Insight. 3(17):. PMID: 30185657.

Abikhair Burgo et al. 2018. JCI Insight. 3(17):. PMID: 30185657.

Mekhdjian et al. 2017. Mol Biol Cell. 28(11):1467-1488. PMID: 28381423.

Proby et al. 2000. Exp Dermatol. 9(2):104-17. PMID: 10772384.


Add a reference